SCHEMBL3787649

SCHEMBL3787649

O=C1NCCN1c1cc2cnccc2s1

nearest known ligand 0.48

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
CYP2A6 P11509 5/20 0.48
CYP17A1 P05093 4/20 0.45
CYP1A2 P05177 2/20 0.40
CYP3A4 P08684 2/20 0.40
TSHR P16473 1/20 0.40
SMN1; SMN2 Q16637 1/20 0.40
HSD17B10 Q99714 1/20 0.40
TGFBR1 P36897 3/20 0.39
PRKCH P24723 2/20 0.35
PRKCE Q02156 2/20 0.35
CCNC P24863 1/20 0.34
CDK8 P49336 1/20 0.34
NAMPT P43490 1/20 0.34
KDM4E B2RXH2 1/20 0.33
PRKD3 O94806 1/20 0.33
PRKCG P05129 1/20 0.33
PRKCB P05771 1/20 0.33
ADORA3 P0DMS8 1/20 0.33
PRKCA P17252 1/20 0.33
PRKACA P17612 1/20 0.33

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL3781998 0.74 CYP17A1 (0.58) CYP2A6CYP17A1
SCHEMBL3787372 0.69 CYP2A6 (0.39) CYP2A6CYP17A1CYP1A2CYP3A4TSHR
SCHEMBL11070896 0.66 CYP2A6 (0.65) CYP2A6CYP1A2CYP3A4TGFBR1CDK8
SCHEMBL2960834 0.66 ADRB2 (0.48) CYP1A2CYP3A4TSHRSMN1; SMN2HSD17B10
SCHEMBL1253313 0.65 CYP2A6 (1.00) CYP2A6CYP3A4TGFBR1CDK8PRKD3
SCHEMBL3781174 0.65 SCN9A (0.40) CYP17A1CYP1A2CYP3A4TSHRSMN1; SMN2
SCHEMBL3573012 0.65 CYP3A4 (0.38) CYP1A2CYP3A4TSHRSMN1; SMN2HSD17B10
SCHEMBL3793736 0.64 CYP17A1 (0.71) CYP17A1
Hydrochloric Acid SCHEMBL27139693 0.64 CYP2A6 (0.62) CYP2A6CYP1A2CYP3A4TGFBR1CDK8
SCHEMBL3778218 0.64 CHRNB2 (0.51)

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 4 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-RE45173-E1 Inhibitors of CYP 17 NOVARTIS AG (CH) 2014-09-30 US disclosed
US-20140228394-A1 INHIBITORS OF CYP 17 NOVARTIS AG (CH) 2014-08-14 US disclosed
US-8263635-B2 Inhibitors of CYP 17 NOVARTIS AG (CH) 2012-09-11 US disclosed
US-20100331326-A1 Inhibitors of CYP 17 NOVARTIS AG 2010-12-30 US disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20100331326-A1 Inhibitors of CYP 17 CYP17A1, CYP21A2, CYP4A22 CYP2A6 51/4885CYP17A1 1/4885CYP1A2 17/4885
US-20140228394-A1 INHIBITORS OF CYP 17 CYP17A1, CYP21A2, CYP4A22 CYP2A6 51/4885CYP17A1 1/4885CYP1A2 17/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.